Karyopharm Therapeutics Inc (NASDAQ: KPTI)’s stock price has plunge by 6.80relation to previous closing price of 1.03. Nevertheless, the company has seen a 18.87% surge in its stock price over the last five trading sessions. prnewswire.com reported 2024-07-05 that – Following its initial approval for the treatment of relapsed/refractory multiple myeloma (R/R MM), XPOVIO® has now received approval as a monotherapy for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) marking the second approved indication of XPOVIO® in China. – Results from the registrational SEARCH study in China showed that the overall response rate (ORR) among the 60 Chinese patients treated with XPOVIO® met the study’s prespecified primary endpoint.
Is It Worth Investing in Karyopharm Therapeutics Inc (NASDAQ: KPTI) Right Now?
Additionally, the 36-month beta value for KPTI is 0.19. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 5 rating it as “overweight,” 0 rating it as “hold,” and 1 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for KPTI is 110.07M and currently, short sellers hold a 17.16% ratio of that float. The average trading volume of KPTI on July 30, 2024 was 1.41M shares.
KPTI’s Market Performance
KPTI’s stock has seen a 18.87% increase for the week, with a 26.79% rise in the past month and a 0.00% fall in the past quarter. The volatility ratio for the week is 6.70%, and the volatility levels for the past 30 days are at 8.53% for Karyopharm Therapeutics Inc The simple moving average for the past 20 days is 21.09% for KPTI’s stock, with a 6.47% simple moving average for the past 200 days.
Analysts’ Opinion of KPTI
Many brokerage firms have already submitted their reports for KPTI stocks, with Piper Sandler repeating the rating for KPTI by listing it as a “Overweight.” The predicted price for KPTI in the upcoming period, according to Piper Sandler is $8 based on the research report published on January 19, 2023 of the previous year 2023.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see KPTI reach a price target of $10, previously predicting the price at $7. The rating they have provided for KPTI stocks is “Outperform” according to the report published on November 04th, 2022.
JP Morgan gave a rating of “Neutral” to KPTI, setting the target price at $8 in the report published on February 09th of the previous year.
KPTI Trading at 13.37% from the 50-Day Moving Average
After a stumble in the market that brought KPTI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.59% of loss for the given period.
Volatility was left at 8.53%, however, over the last 30 days, the volatility rate increased by 6.70%, as shares surge +31.82% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.29% lower at present.
During the last 5 trading sessions, KPTI rose by +16.17%, which changed the moving average for the period of 200-days by -14.68% in comparison to the 20-day moving average, which settled at $0.9214. In addition, Karyopharm Therapeutics Inc saw 27.17% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at KPTI starting from Paulson Richard A., who sale 3,616 shares at the price of $0.85 back on Jul 05 ’24. After this action, Paulson Richard A. now owns 1,146,489 shares of Karyopharm Therapeutics Inc, valued at $3,077 using the latest closing price.
PAKIANATHAN DEEPIKA, the Director of Karyopharm Therapeutics Inc, sale 231,548 shares at $0.95 during a trade that took place back on Jun 07 ’24, which means that PAKIANATHAN DEEPIKA is holding 0 shares at $220,133 based on the most recent closing price.
Stock Fundamentals for KPTI
Current profitability levels for the company are sitting at:
- -0.94 for the present operating margin
- 0.96 for the gross margin
The net margin for Karyopharm Therapeutics Inc stands at -1.04. The total capital return value is set at -0.95.
Based on Karyopharm Therapeutics Inc (KPTI), the company’s capital structure generated 31.19 points at debt to capital in total, while cash flow to debt ratio is standing at -0.67. The debt to equity ratio resting at -1.03. The interest coverage ratio of the stock is -5.53.
Currently, EBITDA for the company is -129.01 million with net debt to EBITDA at -1.15. When we switch over and look at the enterprise to sales, we see a ratio of 2.01. The receivables turnover for the company is 4.52for trailing twelve months and the total asset turnover is 0.69. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.04.
Conclusion
In conclusion, Karyopharm Therapeutics Inc (KPTI) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
